Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06052072 · ClinicalTrials.gov registry record · NA

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)

A NA study of Heart Failure and Group 2 Pulmonary Hypertension, sponsored by Gradient Denervation Technologies.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
8
Study locations

NCT06052072 is a NA study of Heart Failure and Group 2 Pulmonary Hypertension that is actively recruiting participants, run by Gradient Denervation Technologies. The registered enrollment target is 50 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06052072, a NA study of Heart Failure and Group 2 Pulmonary Hypertension, is actively recruiting participants, sponsored by Gradient Denervation Technologies.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
8
Study locations

Study Summary

This early feasibility study is intended to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension

Conditions Studied

Heart Failure Group 2 Pulmonary Hypertension

Interventions

  • DEVICE Gradient Denervation System

Study Locations (8)

Texas

  • Baylor College of Medicine - Houston
  • Houston Methodist - Houston

Wisconsin

  • University of Wisconsin - Madison
  • Aurora Health - Milwaukee

Illinois

  • Northwestern University - Chicago

Massachusetts

  • Massachusetts General Hospital - Boston

North Carolina

  • Duke University - Durham

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-02-20
Est. Completion 2028-07-01
Phase NA

Sponsor

Gradient Denervation Technologies

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06052072

The ClinicalTrials.gov registry entry for NCT06052072 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The listed sponsor is Gradient Denervation Technologies, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Gradient Denervation System is the first listed.

NCT06052072 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Texas, Wisconsin, Illinois.

Frequently Asked Questions

What is clinical trial NCT06052072 about?

NCT06052072 is a clinical study titled "Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)". This early feasibility study is intended to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension

What is the current status of trial NCT06052072?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-02-20. Estimated completion is 2028-07-01.

What conditions does trial NCT06052072 study?

This clinical trial studies the following conditions: Heart Failure, Group 2 Pulmonary Hypertension.

What interventions are being tested in trial NCT06052072?

The interventions under investigation include: Gradient Denervation System (DEVICE).

Who is sponsoring clinical trial NCT06052072?

This trial is sponsored by Gradient Denervation Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06052072 being conducted?

This trial has 8 study locations across Illinois, Massachusetts, North Carolina, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Group 2 Pulmonary Hypertension

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.